The “Venture Capital for Life-Science BioTech” event, held on January 22, 2025, at Fondazione UNIMI, showcased how technological startups are transforming the healthcare landscape. The event featured innovative biotech and MedTech companies that are addressing critical health challenges and attracting venture capital investment. Here are the key highlights from the event:
Capital Cell – The Biotech Revolution
Capital Cell is a leading alternative investment platform specializing in early-stage biotech and life science companies. By leveraging expert selection and visionary backing, it has facilitated investments totaling €112 million across 127 funding rounds, with an impressive 3.04x return on capital. The platform empowers investors to shape the future of healthcare through strategic funding.
MgShell – Transforming Ophthalmic Care
MgShell is addressing the growing issue of age-related macular degeneration (AMD), a leading cause of blindness in individuals over 50. Their innovation is a biodegradable intraocular drug delivery device that eliminates the need for frequent injections, enhancing patient compliance and reducing healthcare costs. By releasing preloaded medication at set intervals, MgShell’s solution offers a non-surgical, efficient alternative to current treatment methods.
NIB Biotech – Revolutionizing Prostate Cancer Detection
NIB Biotech is reshaping prostate cancer diagnosis with its Risk Test, a groundbreaking tool based on proprietary biomarkers. Traditional PSA testing often results in false positives, leading to unnecessary biopsies. The Risk Test is five times more accurate than PSA tests, reducing unnecessary biopsies by 50% and offering a faster, cost-effective solution. Clinical trials are set to begin in 2025.
Rilemo – Bringing Fluid-Related Pathology Diagnosis Closer to Patients
With the rise of chronic diseases and an aging population, Rilemo is developing a portable diagnostic device based on electromagnetic imaging. This innovation allows for safe, patient-centric diagnostics, helping reduce hospital overload and enabling early detection of fluid-related pathologies.
TT3A – A Minimally Invasive Approach to Aortic Repair
TT3A is pioneering the world’s first fully transcatheter device for ascending thoracic aortic aneurysms and dissections (ATAADs). Open-heart surgery remains the standard treatment, but TT3A’s minimally invasive solution aims to reduce mortality and hospitalization rates by 50%. Currently in the pre-clinical phase, the company is focused on demonstrating the feasibility and safety of its technology.
The event highlighted the potential of biotech and MedTech startups in transforming healthcare through innovation. From alternative investment models to groundbreaking diagnostic tools and minimally invasive treatments, these companies exemplify how venture capital is fueling the future of life sciences. With clinical trials and commercialization on the horizon, these pioneering solutions have the potential to redefine patient care worldwide.